Shanghai Junshi Biosciences Co. Ltd (SHJBF PINK) stock market data APIs
$1.9556
0(0%)
as of July 9, 2025
Try our APIs with
free plan!
Shanghai Junshi Biosciences Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Prev. Close
1.9556
Open
1.9556
High
1.9556
Low
1.9556
52 wk Range
1.24-1.97
Market Cap
3 411 M
Shares Outstanding
260 M
Revenue
2 068 M
EPS
-0.0328
Beta
0.598
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Shanghai Junshi Biosciences Co. Ltd data using free add-ons & libraries
Get Shanghai Junshi Biosciences Co. Ltd Fundamental Data
Shanghai Junshi Biosciences Co. Ltd Fundamental data includes:
- Net Revenue: 2 068 M
- EBITDA: -1 051 532 032
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: NaN
Get Shanghai Junshi Biosciences Co. Ltd End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shanghai Junshi Biosciences Co. Ltd News
New
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
Junshi Biosciences SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate
BioDlink congratulates Junshi Biosciences on receiving IND approval from China'sNMPA for JS212, the company's first bispecific ADC. JS212 combines dual-targeting antibody technology with a cytotoxic p...
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
Junshi Biosciences SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical compa...
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
Junshi Biosciences SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
